Atezolizumab-associated Dermatomyositis in Advanced Small-cell Lung Carcinoma

por Yamaguchi, Yoshitaka, Aso, Mari, Nagasawa, Hikaru, Wada, Manabu
Publicado 2021

Relationship between Programmed Cell Death Protein Ligand 1 Expression and Immune-related Adverse Events in Non-small-cell Lung Cancer Patients Treated with Pembrolizumab

por Sugisaka, Jun, Toi, Yukihiro, Taguri, Masataka, Kawashima, Yosuke, Aiba, Tomoiki, Kawana, Sachiko, Saito, Ryohei, Aso, Mari, Tsurumi, Kyoji, Suzuki, Kana, Shimizu, Hisashi, Ono, Hirotaka, Domeki, Yutaka, Terayama, Keisuke, Nakamura, Atsushi, Yamanda, Shinsuke, Kimura, Yuichiro, Honda, Yoshihiro, Sugawara, Shunichi
Publicado 2019

Current status of first‐line treatment with pembrolizumab for non–small‐cell lung cancer with high PD‐L1 expression

por Ikezawa, Yasuyuki, Mizugaki, Hidenori, Morita, Ryo, Tateishi, Kazunari, Yokoo, Keiki, Sumi, Toshiyuki, Kikuchi, Hajime, Kitamura, Yasuo, Nakamura, Atsushi, Kobayashi, Maki, Aso, Mari, Kimura, Nozomu, Yoshiike, Fumiaki, Furuta, Megumi, Tanaka, Hisashi, Sekikawa, Motoki, Hachiya, Tsutomu, Nakamura, Keiichi, Shimokawa, Mototsugu, Oizumi, Satoshi
Publicado 2022

Association of immune‐related pneumonitis with clinical benefit of anti‐programmed cell death‐1 monotherapy in advanced non‐small cell lung cancer

por Ono, Kana, Ono, Hirotaka, Toi, Yukihiro, Sugisaka, Jun, Aso, Mari, Saito, Ryohei, Kawana, Sachiko, Aiba, Tomoiki, Odaka, Tetsuo, Matsuda, Suguru, Saito, Shin, Narumi, Akane, Ogasawara, Takahiro, Shimizu, Hisashi, Domeki, Yutaka, Terayama, Keisuke, Kawashima, Yosuke, Nakamura, Atsushi, Yamanda, Shinsuke, Kimura, Yuichiro, Honda, Yoshihiro, Sugawara, Shunichi
Publicado 2021